<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713424</url>
  </required_header>
  <id_info>
    <org_study_id>00078213</org_study_id>
    <nct_id>NCT03713424</nct_id>
  </id_info>
  <brief_title>The Effects of Clavulanic Acid on Tobacco Use Disorder</brief_title>
  <acronym>CLAV</acronym>
  <official_title>An fMRI Pilot Study of the Effects of Clavulanic Acid on Cigarette Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is looking into the effects of clavulanic on smoking behavior in adult
      cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid
      will reduce smoking over the course of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarette Smoking</measure>
    <time_frame>5 days</time_frame>
    <description>Biochemical smoking assessment (breath carbon monoxide) at each study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of change in fMRI brain response to images</measure>
    <time_frame>4 days</time_frame>
    <description>Measure the effects of Clavulanic Acid on fMRI BOLD response to images (change from baseline to end of study) while participants undergo functional magnetic resonance imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of change in fMRI brain connectivity</measure>
    <time_frame>4 days</time_frame>
    <description>Measure the effects of Clavulanic Acid on resting-state functional connectivity (change from baseline to end of study) while participants undergo functional magnetic resonance imaging.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Clav</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-day 125 bid oral capsule administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4-day, twice-daily oral capsule administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clavulanic Acid</intervention_name>
    <description>Beta lactamase inhibitor for smoking cessation</description>
    <arm_group_label>Clav</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Entry criteria:

        Inclusion Criteria all subjects:

          1. Age 18-65 years

          2. Right Handed

          3. English fluency

          4. Smoke &gt; 10 cigarettes/day for a minimum of 2 yrs and have an expired carbon monoxide
             (CO) concentration of â‰¥ 10 ppm (to confirm inhalation at screening and scanning);

        Exclusion Criteria all subjects:

          1. Sensitivity or allergy to clavulanic acid/antibiotics.

          2. Past head injury or primary neurological disorder associated with MRI abnormalities,
             including dementia, MCI, brain tumors, epilepsy, Parkinson's disease, or demyelinating
             diseases.

          3. Any physical or intellectual disability affecting completion of assessments

          4. Any contraindication to MRI.

          5. Any use of psychotropic substances through positive drug screen (such as marijuana or
             cocaine) or abuse of prescription medications (such as benzodiazepines or opiates)
             within the last month. Diagnosis of substance use disorder (SUD; other than nicotine)

          6. Presence of an untreated illness

          7. Current or past psychosis

          8. Positive pregnancy test (Urine pregnancy testing at screening and prior to fMRI scan).

          9. Use of carbamazepine or nitroglycerin (or any other medication deemed to be hazardous
             if taken with NAC) within 14 days of study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett Froeliger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhura Athreya, MS</last_name>
    <phone>843-792-1608</phone>
    <email>athreya@Musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brett E Froeliger, PhD</last_name>
    <phone>843-7926018</phone>
    <email>froelige@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Froeliger, PhD</last_name>
      <phone>843-792-6018</phone>
      <email>athreya@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Madhura Athreya, MS</last_name>
      <phone>8437921608</phone>
      <email>athreya@musc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>April 18, 2020</last_update_submitted>
  <last_update_submitted_qc>April 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Brett Froeliger</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

